Relief Therapeutics Holding Stock Performance
| RLFTY Stock | USD 5.00 0.68 15.74% |
Relief Therapeutics holds a performance score of 11 on a scale of zero to a hundred. The company holds a Beta of -0.46, which implies possible diversification benefits within a given portfolio. As returns on the market increase, returns on owning Relief Therapeutics are expected to decrease at a much lower rate. During the bear market, Relief Therapeutics is likely to outperform the market. Use Relief Therapeutics value at risk, as well as the relationship between the kurtosis and market facilitation index , to analyze future returns on Relief Therapeutics.
Risk-Adjusted Performance
11 of 100
Weak | Strong |
Good
Compared to the overall equity markets, risk-adjusted returns on investments in Relief Therapeutics Holding are ranked lower than 11 (%) of all global equities and portfolios over the last 90 days. In spite of fairly unsteady basic indicators, Relief Therapeutics showed solid returns over the last few months and may actually be approaching a breakup point. ...more
| Begin Period Cash Flow | 43.2 M | |
| Total Cashflows From Investing Activities | -30.3 M |
Relief |
Relief Therapeutics Relative Risk vs. Return Landscape
If you would invest 262.00 in Relief Therapeutics Holding on September 20, 2024 and sell it today you would earn a total of 238.00 from holding Relief Therapeutics Holding or generate 90.84% return on investment over 90 days. Relief Therapeutics Holding is currently producing 1.5489% returns and takes up 10.8345% volatility of returns over 90 trading days. Put another way, 96% of traded otc stocks are less volatile than Relief, and 70% of all traded equity instruments are likely to generate higher returns over the next 90 trading days. Expected Return |
| Risk |
Relief Therapeutics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Relief Therapeutics' investment risk. Standard deviation is the most common way to measure market volatility of otc stocks, such as Relief Therapeutics Holding, and traders can use it to determine the average amount a Relief Therapeutics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.143
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | RLFTY | |||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 10.83 actual daily | 96 96% of assets are less volatile |
Expected Return
| 1.55 actual daily | 30 70% of assets have higher returns |
Risk-Adjusted Return
| 0.14 actual daily | 11 89% of assets perform better |
Based on monthly moving average Relief Therapeutics is performing at about 11% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Relief Therapeutics by adding it to a well-diversified portfolio.
Relief Therapeutics Fundamentals Growth
Relief OTC Stock prices reflect investors' perceptions of the future prospects and financial health of Relief Therapeutics, and Relief Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Relief OTC Stock performance.
| Return On Equity | -0.33 | |||
| Return On Asset | -0.12 | |||
| Operating Margin | (5.96) % | |||
| Current Valuation | 102.36 M | |||
| Shares Outstanding | 21.96 M | |||
| Price To Book | 0.77 X | |||
| Price To Sales | 19.41 X | |||
| Revenue | 3.32 M | |||
| EBITDA | (33.3 M) | |||
| Cash And Equivalents | 29.87 M | |||
| Cash Per Share | 1.07 X | |||
| Total Debt | 396 K | |||
| Debt To Equity | 0.03 % | |||
| Book Value Per Share | 7.60 X | |||
| Cash Flow From Operations | (35.72 M) | |||
| Earnings Per Share | (1.50) X | |||
| Total Asset | 251.62 M | |||
About Relief Therapeutics Performance
Evaluating Relief Therapeutics' performance through its fundamental ratios, provides valuable insights into its operational efficiency and profitability. For instance, if Relief Therapeutics has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Relief Therapeutics has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
Relief Therapeutics Holding AG, a biopharmaceutical company, provides patients with therapeutic relief from serious diseases with high unmet medical need in Switzerland, rest of Europe, North America, and internationally. The company was founded in 2013 and is based in Geneva, Switzerland. Relief Therapeutics is traded on OTC Exchange in the United States.Things to note about Relief Therapeutics performance evaluation
Checking the ongoing alerts about Relief Therapeutics for important developments is a great way to find new opportunities for your next move. OTC Stock alerts and notifications screener for Relief Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Relief Therapeutics is way too risky over 90 days horizon | |
| Relief Therapeutics appears to be risky and price may revert if volatility continues | |
| The company reported the revenue of 3.32 M. Net Loss for the year was (34.7 M) with profit before overhead, payroll, taxes, and interest of 2.57 M. | |
| Relief Therapeutics Holding has accumulated about 29.87 M in cash with (35.72 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.07. |
- Analyzing Relief Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Relief Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining Relief Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Relief Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Relief Therapeutics' management team can help you assess the OTC Stock's leadership.
- Pay attention to analyst opinions and ratings of Relief Therapeutics' otc stock. These opinions can provide insight into Relief Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Relief OTC Stock Analysis
When running Relief Therapeutics' price analysis, check to measure Relief Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Relief Therapeutics is operating at the current time. Most of Relief Therapeutics' value examination focuses on studying past and present price action to predict the probability of Relief Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Relief Therapeutics' price. Additionally, you may evaluate how the addition of Relief Therapeutics to your portfolios can decrease your overall portfolio volatility.